Citadel Advisors’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.6M | Buy |
516,352
+248,667
| +93% | +$13.1M | ﹤0.01% | 2082 |
|
|
2025
Q4 | $14M | Buy |
267,685
+100,584
| +60% | +$6.02M | ﹤0.01% | 2790 |
|
|
2025
Q3 | $10.8M | Buy |
167,101
+148,223
| +785% | +$8.51M | ﹤0.01% | 3154 |
|
|
2025
Q2 | $918K | Sell |
18,878
-238,669
| -93% | -$9.24M | ﹤0.01% | 7291 |
|
|
2025
Q1 | $8.76M | Sell |
257,547
-621,349
| -71% | -$26.3M | ﹤0.01% | 3031 |
|
|
2024
Q4 | $34.6M | Buy |
878,896
+360,349
| +69% | +$17M | 0.01% | 1607 |
|
|
2024
Q3 | $24.4M | Buy |
518,547
+375,985
| +264% | +$19.1M | ﹤0.01% | 1846 |
|
|
2024
Q2 | $7.7M | Sell |
142,562
-94,538
| -40% | -$5.47M | ﹤0.01% | 3139 |
|
|
2024
Q1 | $16.2M | Sell |
237,100
-36,259
| -13% | -$2.6M | ﹤0.01% | 2315 |
|
|
2023
Q4 | $17.1M | Buy |
273,359
+251,804
| +1,168% | +$13.9M | ﹤0.01% | 2171 |
|
|
2023
Q3 | $978K | Sell |
21,555
-66,410
| -75% | -$3.43M | ﹤0.01% | 6586 |
|
|
2023
Q2 | $4.94M | Sell |
87,965
-86,374
| -50% | -$4.9M | ﹤0.01% | 3677 |
|
|
2023
Q1 | $7.89M | Buy |
174,339
+4,425
| +3% | +$215K | ﹤0.01% | 3126 |
|
|
2022
Q4 | $6.91M | Buy |
169,914
+164,324
| +2,940% | +$8.72M | ﹤0.01% | 3348 |
|
|
2022
Q3 | $365K | Sell |
5,590
-2,618
| -32% | -$190K | ﹤0.01% | 9141 |
|
|
2022
Q2 | $499K | Sell |
8,208
-203,205
| -96% | -$11.9M | ﹤0.01% | 8654 |
|
|
2022
Q1 | $13.3M | Buy |
211,413
+77,094
| +57% | +$4.84M | ﹤0.01% | 2530 |
|
|
2021
Q4 | $10.2M | Sell |
134,319
-83,702
| -38% | -$7.31M | ﹤0.01% | 3048 |
|
|
2021
Q3 | $24.4M | Buy |
218,021
+174,687
| +403% | +$21.9M | 0.01% | 1785 |
|
|
2021
Q2 | $7.01M | Sell |
43,334
-232,439
| -84% | -$28.3M | ﹤0.01% | 3734 |
|
|
2021
Q1 | $33.6M | Buy |
275,773
+209,209
| +314% | +$31.6M | 0.01% | 1411 |
|
|
2020
Q4 | $10.2M | Buy |
66,564
+32,291
| +94% | +$3.82M | ﹤0.01% | 2621 |
|
|
2020
Q3 | $2.87M | Buy |
34,273
+20,968
| +158% | +$1.86M | ﹤0.01% | 4055 |
|
|
2020
Q2 | $978K | Sell |
13,305
-19,344
| -59% | -$1.13M | ﹤0.01% | 5869 |
|
|
2020
Q1 | $1.39M | Sell |
32,649
-174,609
| -84% | -$9.02M | ﹤0.01% | 4762 |
|
|
2019
Q4 | $12.6M | Buy |
+207,258
| New | +$11.3M | 0.01% | 1960 |
|
|
2019
Q1 | – | Sell |
-61,508
| Closed | -$2.13M | – | 9329 |
|
|
2018
Q4 | $1.76M | Buy |
61,508
+33,233
| +118% | +$1.16M | ﹤0.01% | 4356 |
|
|
2018
Q3 | $1.25M | Sell |
28,275
-67,206
| -70% | -$3.52M | ﹤0.01% | 5157 |
|
|
2018
Q2 | $5.61M | Buy |
95,481
+41,785
| +78% | +$2.38M | ﹤0.01% | 2598 |
|
|
2018
Q1 | $2.45M | Buy |
53,696
+13,885
| +35% | +$573K | ﹤0.01% | 3423 |
|
|
2017
Q4 | $935K | Buy |
+39,811
| New | +$756K | ﹤0.01% | 4745 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Citadel Advisors's CRSP Position: Q1 2026 in Review
Citadel Advisors increased its CRISPR Therapeutics (CRSP) stake by 93% in Q1 2026, buying an estimated $13.1M and bringing the position to 516,352 shares worth $24.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2082.
Citadel Advisors first reported a position in CRSP in Q4 2017 and has held it in 31 quarters since. The position peaked at $34.6M in Q4 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- Citadel Advisors held 516,352 shares of CRISPR Therapeutics worth $24.6M as of Q1 2026.
- Citadel Advisors bought 248,667 CRISPR Therapeutics shares in Q1 2026, an estimated $13.1M.
- CRISPR Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2082 holding.
- Citadel Advisors first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 31 quarters since.
- Citadel Advisors's CRISPR Therapeutics position peaked at $34.6M in Q4 2024.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.